Differential expression of MMP-2 and MMP-9 activity in megakaryocytes and platelets

Blood

Volumn 118, Issue 24, 2011, Pages 6470-6471

  Mannello, Ferdinando ^a   Medda, Virginia ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EDETIC ACID; ENZYME PRECURSOR; GELATINASE A; GELATINASE B; MESSENGER RNA; ORTHOVANADIC ACID; THROMBIN; TRANSCRIPTOME; VANADATE SODIUM;

CELL LYSATE; CELLULAR DISTRIBUTION; CHELATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; LETTER; MEGAKARYOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; THROMBOCYTE; UMBILICAL CORD BLOOD;

EID: 83455201524     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-366195     Document Type: Letter

References (10)

1. Cecchetti L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood. 2011;118(7):1903-1911.
2. Fernandez-Patron C, Martinez-Cuesta MA, Salas E et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost. 1999;82(6):1730-1735.
3. Sheu JR, Fong TH, Liu CM et al. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies. Br J Pharmacol. 2004;143(1):193-201. (Pubitemid 39280039)
4. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res. 2008;121(4):535-542. (Pubitemid 351174273)
5. Mannello F. Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol. 2008;28(4):611-614. (Pubitemid 351651318)
6. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon? Recent Pat Anticancer Drug Discov. 2006;1(1):91-103.
7. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011;278(1):28-45.
8. Chintala SK, Kyritsis AP, Mohan PM et al. Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: modulation of migration and invasion of human malignant glioma cells. Mol Carcinog. 1999;26(4):274-285.
9. Cruz TF, Mills G, Pritzker KP, Kandel RA. Inverse correlation between tyrosine phosphorylation and collagenase production in chondrocytes. Biochem J. 1990;269(3):717-721. (Pubitemid 20236082)
10. Mannello F, Luchetti F, Canonico B, Falcieri E, Papa S. Measurements, zymographic analysis, and characterization of matrix metalloproteinase-2 and -9 in healthy human umbilical cord blood. Clin Chem. 2004;50(9):1715-1717. (Pubitemid 39121261)